258 320
Table 2 (
Continued
)
Study
Overall PCa
prevalence (%)
Reporting
level
Multiparametric MRI performance for PCa detection
Definition of csPCa csPCa prevalence
Multiparametric MRI performance for csPCa detection
TN
FN
TP
FP
NPV
PPV
TN
FN
TP
FP
NPV
PPV
Abd-Alazeez
(2014)
[13]
54.7
Lobe
3/5: 33
3/5: 14 3/5: 127
3/5: 84
3/5: 70% 3/5: 60% Def 1: GS 4 + 3 and/
or max CCL 6 mm
Def 2: GS 3 + 4
and/or max CCL
4 mm
Def 3: GS 4 + 3
Def 4: GS 3 + 4
Def 5: max CCL
6 mm
Def 6: max CCL
4 mm
Def 1: NR
Def 2: 44.2%
Def 3: 23.2%
Def 4: 36%
Def 5: 32.9%
Def 6: 39.5%
Def 1: 46
Def 2: 42
Def 3: 47
Def 4: 43
Def 5: 46
Def 6: 43
Def 1: 1
Def 2: 5
Def 3: 0
Def 4: 4
Def 5: 1
Def 6: 4
Def 1: 45
Def 2: 72
Def 3: 13
Def 4: 50
Def 5: 39
Def 6: 59
Def 1: 166
Def2: 139
Def 3: 198
Def 4: 161
Def 5: 172
Def 6: 152
Def 1: 98
Def 2: 89
Def 3: 100
Def 4: 92
Def 5: 98
Def 6: 91
Def 1: 21
Def 2: 34
Deg 3: 6
Def 4: 24
Def 5: 19
Def 6: 28
4/5: 87
3/5: 62 3/5: 79
3/5: 30
3/5: 58% 3/5: 73%
Def 1: 140
Def 2: 124
Def 3: 148
Def 4: 133
Def 5: 141
Def 6: 131
Def 1: 9
Def 2: 25
Def 3: 1
Def 4: 16
Def 5: 8
Def 6: 18
Def 1: 37
Def 2: 52
Def 3: 12
Def 4: 38
Def 5: 32
Def 6: 45
Def 1: 72
Def 2: 57
Def 3: 97
Def 4: 71
Def 5: 77
Def 6: 64
Def 1: 94
Def 2: 83
Def 3: 99
Def 4: 89
Def 5: 95
Def 6: 88
Def 1: 34
Def 2: 48
Def 3: 11
Def 4: 35
Def 5: 30
Def 6: 42
Abd-Alazeez
(2014)
[12]
47.2
Lobe
3/5: 26
3/5: 13 3/5: 38
3/5: 31
3/5: 66% 3/5: 55% Def 1: GS 4 + 3
and/or max CCL
6 mm
Def 2: GS 3 + 4
and/or max CCL
4 mm
Def 3: GS 4 + 3
Def 4: GS 3 + 4
Def 5: max CCL
6 mm
Def 6: max CCL
4 mm
Def 1: 18.5%
Def 2: 31.5%
Def 3: 4.6%
Def 4: 21.3%
Def 5: 16.7%
Def 6: 25%
Def 1: 37
Def 2: 31
Def 3: 39
Def 4: 36
Def 5: 37
Def 6: 32
Def 1: 2
Def 2: 8
Def 3: 0
Def 4: 3
Def 5: 2
Def 6: 7
Def 1: 18
Def 2: 26
Def 3: 5
Def 4: 20
Def 5: 16
Def 6: 20
Def 1: 51
Def 2: 43
Def 3: 64
Def 4: 49
Def 5: 53
Def 6: 49
Def 1: 95
Def 2: 79
Def 3: 100
Def 4: 92
Def 5: 95
Def 6: 82
Def 1: 26
Def 2: 38
Def 3: 7
Def 4: 29
Def 5: 23
Def 6: 29
4/5: 49
4/5: 25 4/5: 26
4/5: 8
4/5: 66% 4/5: 76%
Def 1: 70
Def 2: 63
Def 3: 73
Def 4: 68
Def 5: 70
Def 6: 64
Def 1: 4
Def 2: 11
Def 3: 1
Def 4: 6
Def 5: 4
Def 6: 10
Def 1: 16
Def 2: 23
Def 3: 4
Def 4: 17
Def 5: 14
Def 6: 17
Def 1: 18;
Def 2: 11
Def 3: 30
Def 4: 17
Def 5: 20
Def 6: 17
Def 1: 94
Def 2: 85
Def 3: 99
Def 4: 92
Def 5: 94
Def 6: 86
Def 1: 47
Def 2: 67
Def 3: 12
Def 4: 50
Def 5: 41
Def 6: 49
Matsuoka (2014)
[37]
64.8
Lobe
46
49
149
26
48.4%
85.1%
NR
NR
NR
NR
NR
NR
NR
NR
Junker (2013)
[30]
53.4
Patient
10/15: 21
11/15: 28
10/15: 4
11/15: 12
10/15: 35
11/15: 27
10/15: 13
11/15: 6
10/15: 84%
11/15: 70%
10/15:
72.9%
11/15:
81.8%
GS 4 + 3
13.7%
13: 54 13: 2 13: 8
13: 9
13: 96.4% 13: 47%
Busetto (2013)
[16]
41.7
Patient 59
7
61
36
89%
63%
NR
NR
NR
NR
NR
NR
NR
NR
Rais-Bahrami
(2013)
[47]
54.2
Patient
2/4
:
80
2/4: 275 2/4: 187
2/4: 275 2/4: 66% 2/4: 59% GS 7:
GS 8
31.7%
NR
NR
NR
NR
GS 7: 91%
GS 8: 91%
GS 7: 38%
GS 8: 18%
3/4: 251 3/4: 76 3/4: 16
3/4: 76
3/4: 51% 3/4: 82%
NR
NR
NR
NR
GS 7: 75%
GS 8: 91%
GS 7: 67%
GS 8: 41%
Kuru (2013)
[34]
57.6
Patient 80
14
67
186
85.1%
73.5%
NR
NR
NR
NR
NR
NR
NR
NR
Ferda (2013)
[20]
51.2
Patient 52
2
82
28
96.3%
74.5%
NR
NR
NR
NR
NR
NR
NR
NR
Ganie (2013)
[21]
74.7
Patient 13
3
62
9
59.1%
95.4%
NR
NR
NR
NR
NR
NR
NR
NR
Vinet (2013)
[57]
49.3
Patient
3/5: 11
3/5: 6
3/5: 28
3/5: 24
3/5: 64.7% 3/5: 53.8% NR
NR
NR
NR
NR
NR
NR
NR
4/5: 22
4/5: 11 4/5: 23
4/5: 13
4/5: 66.7% 4/5: 63.8% NR
NR
NR
NR
NR
NR
NR
NR
Numao (2013)
[38]
45
Patient 137
57
101
56
70.6%
64.3%
Def 1: GS 4 + 3 and/
or 20% positive
cores and/or max CCL
5 mm
Def 2: GS 3 + 4 and/
or 20% + cores
and/or max CCL 5 mm
Def 3: GS 3 + 4 and/
or 20% + cores
Def 1: 33.3%
Def 2:37.8%
Def 3: 35.8%
Def 1: 74
Def 2: 65
Def 3: 69
Def 1: 83
Def 2: 92
Def 3: 88
Def 1: 160
Def 2: 153
Def 3: 156
Def 1: 34
Def 2: 41
Def 3: 38
Def 1: 82.4%
Def 2: 78.8%
Def 3: 80.4%
Def 1: 58.8%
Def 2: 58.5%
Def 3: 56%
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 2 5 0 – 2 6 6
258